Knockout of Mitochondrial Thioredoxin Reductase Stabilizes Prolyl Hydroxylase 2 and Inhibits Tumor Growth and Tumor-Derived Angiogenesis

Antioxidants and Redox Signaling

Volumn 22, Issue 11, 2015, Pages 938-950

  Hellfritsch, Juliane ^a   Kirsch, Julian ^a   Schneider, Manuela ^a   Fluege, Tamara ^b   Wortmann, Markus ^a   Frijhoff, Jeroen ^c   Dagnell, Markus ^c   Fey, Theres ^a   Esposito, Irene ^b,d   Kölle, Pirkko ^a   Pogoda, Kristin ^a   Angeli, José Pedro Friedmann ^d   Ingold, Irina ^d   Kuhlencordt, Peter ^a   Östman, Arne ^c   Pohl, Ulrich ^a   Conrad, Marcus ^b,d   Beck, Heike ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c KAROLINSKA INSTITUTE   (Sweden)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAREDOXIN; GLUTAREDOXIN 2; GLUTATHIONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; THIOREDOXIN; THIOREDOXIN REDUCTASE 2; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; EGLN1 PROTEIN, MOUSE; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; REACTIVE OXYGEN METABOLITE; TXNRD2 PROTEIN, MOUSE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; GENE SILENCING; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); TRANSGENIC MOUSE; XENOGRAFT;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MICE; MICE, TRANSGENIC; MITOCHONDRIA; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; REACTIVE OXYGEN SPECIES; THIOREDOXIN REDUCTASE 2;

EID: 84926322394     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.5889     Document Type: Article

References (53)

1. Arner ES and Holmgren A. The thioredoxin system in cancer-introduction to a thematic volume of Seminars in Cancer Biology. Semin Cancer Biol 16: 419, 2006.
2. Beck H, Acker T, Wiessner C, Allegrini PR, and Plate KH. Expression of angiopoietin-1, angiopoietin-2, and tie receptors after middle cerebral artery occlusion in the rat. Am J Pathol 157: 1473-1483, 2000.
3. Belaiba RS, Bonello S, Zahringer C, Schmidt S, Hess J, Kietzmann T, and Gorlach A. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 18: 4691-4697, 2007.
4. Brauchle M, Funk JO, Kind P, and Werner S. Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem 271: 21793-21797, 1996.
5. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, Scarpulla RC, and Chandel NS. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 1: 409-414, 2005.
6. Cairns RA, Harris IS, and Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95, 2011.
7. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, and Giaccia AJ. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 15: 527-538, 2009.
8. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, and Schumacker PT. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem 275: 25130-25138, 2000.
9. Choi JH, Kim TN, Kim S, Baek SH, Kim JH, Lee SR, and Kim JR. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res 22: 3331-3335, 2002.
10. Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjac A, Schneider M, Beck H, Hatzopoulos AK, Just U, Sinowatz F, Schmahl W, Chien KR, Wurst W, Bornkamm GW, and Brielmeier M. Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol 24: 9414-9423, 2004.
11. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, and Taylor CT. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A 103: 18154-18159, 2006.
12. D'Autreaux B and Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 8: 813-824, 2007.
13. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, and Tuveson DA. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106-109, 2011.
14. Drechsel DA and Patel M. Respiration-dependent H2O2 removal in brain mitochondria via the thioredoxin/peroxiredoxin system. J Biol Chem 285: 27850-27858, 2010.
15. Duyndam MC, Hulscher TM, Fontijn D, Pinedo HM, and Boven E. Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1alpha protein by the oxidative stressor arsenite. J Biol Chem 276: 48066-48076, 2001.
16. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, Lee LA, Semenza GL, and Dang CV. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12: 230-238, 2007.
17. Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, Pouyssegur J, Yaniv M, and Mechta-Grigoriou F. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118: 781-794, 2004.
18. Ginouves A, Ilc K, Macias N, Pouyssegur J, and Berra E. PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis. Proc Natl Acad Sci U S A 105: 4745-4750, 2008.
19. Gorlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, Kietzmann T, and Busse R. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smoothmuscle cells: role of the p22(phox)-containing NADPH oxidase. Circ Res 89: 47-54, 2001.
20. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, and Schumacker PT. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 1: 401-408, 2005.
21. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
22. Hanschmann EM, Lonn ME, Schutte LD, Funke M, Godoy JR, Eitner S, Hudemann C, and Lillig CH. Both thioredoxin 2 and glutaredoxin 2 contribute to the reduction of the mitochondrial 2-Cys peroxiredoxin Prx3. J Biol Chem 285: 40699-40705, 2010.
23. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, and Jelkmann W. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 94: 1561-1567, 1999.
24. Huang LE, Arany Z, Livingston DM, and Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271: 32253-32259, 1996.
25. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, and Kaelin WG, Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468, 2001.
26. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, and Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
27. Kamata H, Honda S, Maeda S, Chang L, Hirata H, and Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120: 649-661, 2005.
28. Land H, Parada LF, and Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304: 596-602, 1983.
29. Li L, Shoji W, Takano H, Nishimura N, Aoki Y, Takahashi R, Goto S, Kaifu T, Takai T, and Obinata M. Increased susceptibility of MER5 (peroxiredoxin III) knockout mice to LPS-induced oxidative stress. Biochem Biophys Res Commun 355: 715-721, 2007.
30. Liou GY and Storz P. Reactive oxygen species in cancer. Free Radic Res 44: 479-496, 2010.
31. Mandal PK, Schneider M, Kolle P, Kuhlencordt P, Forster H, Beck H, Bornkamm GW, and Conrad M. Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res 70: 9505-9514, 2010.
32. Mannes AM, Seiler A, Bosello V, Maiorino M, and Conrad M. Cysteine mutant of mammalian GPx4 rescues cell death induced by disruption of the wild-type selenoenzyme. FASEB J 25: 2135-2144, 2011.
33. Manning AM and Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2: 554-565, 2003.
34. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT, and Simon MC. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab 1: 393-399, 2005.
35. Mecinovic J, Chowdhury R, Flashman E, and Schofield CJ. Use of mass spectrometry to probe the nucleophilicity of cysteinyl residues of prolyl hydroxylase domain 2. Anal Biochem 393: 215-221, 2009.
36. Nonn L, Williams RR, Erickson RP, and Powis G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol Cell Biol 23: 916-922, 2003.
37. Nytko KJ, Maeda N, Schlafli P, Spielmann P, Wenger RH, and Stiehl DP. Vitamin C is dispensable for oxygen sensing in vivo. Blood 117: 5485-5493, 2011.
38. Pan Y, Mansfield KD, Bertozzi CC, Rudenko V, Chan DA, Giaccia AJ, and Simon MC. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol 27: 912-925, 2007.
39. Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, and Campisi J. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 5: 741-747, 2003.
40. Perera RM and Bardeesy N. Cancer: when antioxidants are bad. Nature 475: 43-44, 2011.
41. Pugh CW and Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677-684, 2003.
42. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-2606, 1998.
43. Sandin A, Dagnell M, Gonon A, Pernow J, Stangl V, Aspenstrom P, Kappert K, and Ostman A. Hypoxia followed by re-oxygenation induces oxidation of tyrosine phosphatases. Cell Signal 23: 820-826, 2011.
44. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8: S62-S67, 2002.
45. Stanley BA, Sivakumaran V, Shi S, McDonald I, Lloyd D, Watson WH, Aon MA, and Paolocci N. Thioredoxin reductase- 2 is essential for keeping low levels of H(2)O(2) emission from isolated heart mitochondria. J Biol Chem 286: 33669-33677, 2011.
46. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27: 502-522, 1969.
47. Trachootham D, Alexandre J, and Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591, 2009.
48. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Bjorling L, and Ponten F. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28: 1248-1250, 2010.
49. Valdman A, Haggarth L, Cheng L, Lopez-Beltran A, Montironi R, Ekman P, and Egevad L. Expression of redox pathway enzymes in human prostatic tissue. Anal Quant Cytol Histol 31: 367-374, 2009.
50. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, and Sawyers CL. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11: 555-569, 2007.
51. Wang GL, Jiang BH, and Semenza GL. Effect of altered redox states on expression and DNA-binding activity of hypoxia-inducible factor 1. Biochem Biophys Res Commun 212: 550-556, 1995.
52. Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR, and Jiang BH. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 67: 10823-10830, 2007.
53. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, and Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.